InvestorsHub Logo
Followers 0
Posts 321
Boards Moderated 0
Alias Born 05/16/2016

Re: None

Friday, 02/02/2018 8:44:22 PM

Friday, February 02, 2018 8:44:22 PM

Post# of 9949
Monthly progress report on CSE for IN Quote :

"The Company welcomes such a positive response from the investment community," stated Eric A. Adams, President & CEO, "We are very pleased to be in a position to close the financing, on an oversubscribed basis, so quickly. With this financing, InMed is well positioned with a strong balance sheet to continue to execute on corporate objectives. We have significantly extended the cash runway for our lead programs, INM-750 for EB and biosynthesis, and will be able to make significant advancements for both INM-085 for glaucoma and INM-405 for pain." The Company also intends to use the net proceeds from the private placement for general working capital and corporate purposes, and to seek a listing of its common shares on the Toronto Stock Exchange.

http://thecse.com/sites/default/files/CNSX_Form_7_-_Monthly_Progress_Report_Jan_2018.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INM News